Abstract
We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism of viral replication inhibition. This was a randomized, double-blind, placebo-controlled, dose-ranging study in treatment-naive HIV-infected patients. Participants were assigned to eight groups; each group included eight subjects receiving either the study compound, ABX464 (n = 6), or the corresponding placebo (n = 2), according to a randomization code. The first dose administered was 25 mg, given once or 3 times a day over a 2- to 3-week period. Ascending doses of up to 150 mg were delivered after review of the safety data. The primary objective of the study was to assess the safety and tolerability of ABX464 after repeated oral administrations in subjects infected by HIV. Sixty-six subjects were enrolled and were randomized. Sixty-three subjects completed the study according to the study protocol. Twenty-one adverse events (AEs) were reported by 7 subjects out of 16 (44%) who received placebo, and 158 AEs were reported by 39 subjects out of 50 (78%) who received the study drug. In the ABX464 treatment group, all of these adverse events were mild to moderate. No subjects discontinued treatment due to drug-related AEs. Admi...Continue Reading
References
Jan 20, 2010·The FEBS Journal·Jamal TaziChristiane Branlant
Oct 22, 2010·AIDS·Tae-Wook ChunAnthony S Fauci
Jan 25, 2011·Journal of the International AIDS Society·Sharon R LewinNicolas Chomont
Jan 1, 2011·Frontiers in Plant Science·Youssef Chebli, Anja Geitmann
Dec 12, 2012·Current Opinion in Infectious Diseases·Fumiyo NakagawaAndrew Phillips
Dec 29, 2012·Drug Discovery Today·Sifei Xing, Robert F Siliciano
Mar 13, 2013·Nature Reviews. Genetics·Michaela Müller-McNicoll, Karla M Neugebauer
Apr 25, 2013·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Liang Shan, Robert F Siliciano
Apr 23, 2014·Nucleic Acids Research·Ichiro TaniguchiMutsuhito Ohno
Nov 18, 2014·Nature Reviews. Microbiology·Nancie M ArchinDavid M Margolis
Apr 19, 2015·Retrovirology·Noëlie CamposJamal Tazi
May 21, 2015·Nature Immunology·Tae-Wook ChunAnthony S Fauci
Dec 1, 2015·Nature Reviews. Microbiology·Melissa J ChurchillRonald Swanstrom
Dec 2, 2015·The Journal of Antimicrobial Chemotherapy·John WilkinsonRobert L Murphy
Feb 10, 2016·AIDS Research and Therapy·Gabriela KhouryJohn Wilkinson
Mar 30, 2016·Current Opinion in Virology·Tomas Cihlar, Marshall Fordyce
Mar 30, 2016·Current Opinion in HIV and AIDS·Guinevere Q Lee, Mathias Lichterfeld
Jun 4, 2016·Current Opinion in HIV and AIDS·Joseph K Wong, Steven A Yukl
Oct 25, 2016·Journal of AIDS & Clinical Research·Collins C IwujiMarie-Louise Newell
Nov 2, 2016·Antimicrobial Agents and Chemotherapy·Didier ScherrerHartmut J Ehrlich
Dec 22, 2016·The Journal of Antimicrobial Chemotherapy·Didier ScherrerHartmut J Ehrlich
Citations
Feb 8, 2018·Expert Opinion on Therapeutic Patents·Xiaofang ZuoPeng Zhan
Jul 6, 2018·Journal of Pathogens·Noel Jacques Awi, Sin-Yeang Teow
Mar 21, 2019·Viruses·Aurélie DelannoyBrendan Bell
Jan 30, 2019·Scientific Reports·Audrey VautrinJamal Tazi
Feb 13, 2020·Viruses·Roland SchwarzerWarner C Greene
Sep 22, 2018·Nucleic Acids Research·Daniela Toro-AscuyRicardo Soto-Rifo
Jan 3, 2021·Drug Discovery Today·Jamal TaziDidier Scherrer
Apr 12, 2021·Pharmacological Reports : PR·Sahana PaiK Sreedhara Ranganath Pai